Our client:

Oxford Biomedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and bioprocessing. The Company was one of the first in the UK biotech sector to go public and the existing Chair felt it was time to bring in new expertise and networks to drive the company forward.


The challenge:

The RSA Group was appointed to find a new Chair for Oxford Biomedica’s Board at a time of significant change for the company, making the search a challenging one. In addition, the new appointee would need to meet a closely defined profile and to have experience and credibility in the US where Independent Directors’ compensation almost always includes stock but OXB were unable to offer that. Additionally, the individual would need strategic expertise to reposition the Company’s mixed business model of drug development and bioprocessing to create a clear strategic path for the future that would be attractive to investors.


How our approach made a difference:

We began by conducting a global search, looking for individuals at companies with platform technologies and therapeutics that had shown a significant increase in shareholder value. By developing an in-depth of understanding Oxford Biomedica’s strategic needs, we were able to provide a shortlist of suitable candidates well within the company’s timeframe. As a result Lorenzo Tallarigio was appointed as the new Chair with extensive strategic experience and investor credibility was appointed. The company went on to establish a clear and more compelling strategic direction and has seen a significant increase in Market Cap.


Share this: